Articulating the JACC Journals’ Direction in Times of Global Change

Funding

Dr Krumholz has received research grants from Johnson and Johnson, Agency for Healthcare Research and Quality, Yale-New Haven Hospital contracts, NHLBI, and National Institute of Biomedical Imaging and Bioengineering, Novartis (unpaid) , and Pfizer (unpaid) ; has received consultant fees/honoraria from Element Science, Eye-dentify, and Journal Watch Cardiology; and has ownership interest/partnership/principal in Refactor Health. Dr Ky has received research funding from Pfizer, NIH, PCORI, and AHA. Dr Mann has received consultant fees/honoraria from Cardurion Pharmaceuticals, Novo Holdings, Haya Therapeutics, and Tenaya. Dr Moliterno has served on a data safety monitoring board for Janssen; and has received compensation for serving as an officer, director, trustee, or other fi-duciary role for the U.S. Food and Drug Administration. Dr Tang has received consultant fees/honoraria from Shenqi Medical Technology, Medtronic, Abbott Structural Heart, Boston Scientific, Edwards Life-sciences, Peija Medical, Shockwave Medical, and NeoChord (unpaid) ; has served on a Speakers Bureau for Abbott Structural Heart, Medtronic, and Siemens Healthineers; and has served on advisory boards for Abbott Structural Heart and Medtronic. Dr Shivkumar has been a consultant for nference and Anumana. Dr Silversides has received modest consultant fees/honoraria from UpToDate. Dr Bozkurt has received consultant fees/honoraria from Abiomed, Amgen, Bayer, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Merck & Co, Regeneron, Roche, scPharmaceuticals, Sanofi, and Zoll/Respicardia; has served on data safety monitoring boards for Cardurion, Novo Nordisk, Ren-ovacor, and Roche; has served on a clinical events committee for Abbott; and has received honoraria from Boehringer Ingelheim Pharmaceuticals and Vifor Pharma. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.